Xcout Intel
GenrAb, Inc.
GenrAb, Inc. is a Dallas, Texas-based developer focused on creating first-in-class neuroprotective therapies. The company recently completed significant private financing to accelerate the development of its therapeutic pipeline.
Subscribe to see GenrAb, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
GenrAb, Inc. at a glance
GenrAb, Inc. is a biotechnology company headquartered in United States. It has raised at least $10.2M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $5.6M in April 2025. Xcout tracks 7 named people at GenrAb, Inc., including Dr. Benjamin Greenberg (CEO/CMO).
GenrAb, Inc. leadership
- Dr. Benjamin GreenbergCEO/CMO
- Larry TiffanyChief Executive Officer
- Rich VincentCFO
- Richard VincentCFO and Secretary
- Dr. Nancy MonsonCSO
- Mr. Neil WarmaGenrAb Board Director
1 more named person on record for GenrAb, Inc., with roles, board committees and tenure — see the full roster →
GenrAb, Inc. funding rounds
At least $10.2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $5.6M | 5 named | |
| SEC Form D filing | $4.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
GenrAb, Inc. competitors
A few of GenrAb, Inc.'s closest competitors — see the full list of competitors and alternatives →
Neurona Therapeutics Inc. is a biotherapeutics company that focuses on developing cell-based therapies to address neurological disorders.
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
Novoron Bioscience, Inc. is a San Diego-based biotechnology company developing novel therapeutics to address central nervous system and other conditions.
Memgen, Inc. is a biotechnology research company focused on drug pipelines and science development programs, headquartered in Houston, Texas.
ProteKt Therapeutics is a biotechnology company founded in 2014 and headquartered in Beni-Brak, Israel, that develops novel therapeutics focusing on the nervous system and cellular protection.
Get GenrAb, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on GenrAb, Inc. in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access